Objective. The authors examined ancestry informative markers (AIMs) to estimate the amount of population admixture and control for this heterogeneity for stage and survival in a primary head and neck squamous cell carcinoma (HNSCC) cohort.
C ancer rates of the head and neck are traditionally linked to public health issues. In the United States, in 2010, an estimated 49,260 people (35, 530 men and 13,730 women) will develop head and neck cancer, and an estimated 11,480 deaths (8300 men and 3180 women) occurred. 2 Despite considerable efforts, the 5-year survival rate for HNSCC has not changed significantly. In addition to tobacco and alcohol, 3, 4 epidemiological and laboratory evidence now warrants the conclusion that the human papilloma virus (HPV) is a causative agent for some HNSCCs 5, 6 and an independent risk factor for oropharyngeal HNSCC. [7] [8] [9] The biologic significance of HPV as another independent risk factor is underscored by the improved prognosis for patients with HPV-positive HNSCC relative to HPV-negative HNSCC, 6, 7, 10, 11 due in part to a better therapeutic response to chemoradiotherapy. 12 HNSCC remains a disfiguring disease with a high mortality rate and disparate unfavorable diagnosis and prognosis outcomes for African Americans (AAs). 13, 14 There is no consensus on the causes of the differences in the higher incidence of and the mortality from HNSCC for AAs when compared with Caucasian Americans (CAs), 15 but they may include differences in access to care, stage at diagnosis, insurance status, attitudes of health providers, and HPV infection status. 16 A recent study found that poorer survival outcomes for AA vs CA with oropharyngeal tumors were attributable to racial differences in the prevalence of HPV-positive tumors. HPV positivity was higher in CA (34%) as compared with 4% in AA, and HPV-negative AA and CA patients had similar survival outcomes. 16 Recent genetic association studies have recommended adjusting for population stratification as a strategy for minimizing spurious association. 17, 18 Racial categories are usually based on self-reports, and although this standard is appropriate for studying race and ethnicity as social phenomena, it does not allow for the critical scientific investigation of their biological accuracy.
Over the past 10 years, many groups have developed and characterized sets of single-nucleotide polymorphism (SNP) markers that can distinguish genetic ancestry among major ethnic groups (called ancestry informative markers [AIMs]). 19 These studies also showed the ability of small sets of AIMs to separate a variety of self-identified subjects of European, Amerindian, East Asian, and West African ancestry. Using these SNPs, many are able to provide admixture information for West African, European, and Amerindian admixed populations and perform structured association testing in the context of mixed or admixed population groups. [20] [21] [22] [23] Using genetic markers to probe ancestry in cancer studies affords increased statistical power, permitting inclusion of biologically ill-defined notions of race or ethnicity as a continuous variable rather than a single choice. 24 It is cautioned, however, that race is not equal to genetics and that genetic markers do not define specific races but are proxies for shared ancestry. 24 Therefore, the finding of racial differences is simply a first clue for follow-up studies to disentangle whether the differences have biological or environmental underpinnings. 24 Given the heterogeneity in the AA population, for evaluation of health disparities, genetic ancestry rather than selfreported racial designation can reduce potential confounding effects due to population admixture. In this study, we examined diagnosis (late vs early stage) and prognosis (overall survival) outcomes for AAs with HNSCC based on self-reported race and genetic markers of West African ancestry based on a panel of 100 previously validated AIMs markers to estimate and control for differences in genetic background.
Material and Methods

Study Population
The study cohort of 358 primary HNSCCs was drawn from a multiethnic (37% African American) primary care patient population. Cases were diagnosed by surgical biopsies in the Henry Ford Health System between 1988 and 2005 and followed from 4 to 21 years (through August 2009). 25 Eligibility into the study required that patients have tumor DNA available for the examination of the molecular characteristics of the tumor.
Self-reported race as CA, AA, or other was obtained from the Henry Ford Health System Corporate Data Store and/or the medical record. This study was approved by the Henry Ford Health System Institutional Review Board (IRB #2218).
Genetic Markers of Ancestry
DNA from paraffin-embedded tissue blocks was genotyped using 100 carefully selected ancestry informative markers for all samples. These autosomal markers have previously been used to extract continental ancestry information in AAs and genotyped using published methods. 26, 27 
Variables of Interest
Of particular interest are associations between variables reflecting "race" (either self-report or the West African genetic ancestry [0%-100%] based on AIMs) and outcomes, stage at diagnosis (American Joint Committee on Cancer), and survival time.
Statistical Considerations
Individual genetic ancestry was determined for each person using 100 ancestry informative markers for West African (WA) and European genetic ancestry. [27] [28] [29] [30] Individual ancestry was estimated from the genotype data using the Bayesian Markov chain Monte Carlo method implemented in the program STRUCTURE 2.1. 31 STRUCTURE 2.1 was run under the admixture model using prior population information and independent allele frequencies. We ran the Bayesian Markov chain Monte Carlo method using K = 2 parental populations and a burn-in length of 30 000 for 70 000 repetitions. 27 Each participant was then scored from 0% to 100% on individual ancestry estimates of WA ancestry.
The associations with stage and with time to death were assessed using logistic and Cox regression models, respectively, for inferences about the relationship of gender, age (3 categories: ≤50, 51 to <65, >65 years), smoking (never smokers, past smokers, current smokers), marital status, race, genetic race (continuous variable), and tumor site (5 sites: larynx, oral cavity [OC], oropharynx [OP], hypopharynx [HP], and site as other [lip-external, nose maxilla, nasopharynx, sinonasal]). Associations with self-reported race were tested with t tests (or Wilcoxon rank tests) and with χ 2 tests. Subgroup analyses for diagnosis (late vs early stage) and survival (time to death) were performed for African Americans with WA genetic ancestry values ≥15%.
Results
Final Cohort
Of the 358 primary HNSCCs, 13 were subsequently found to not meet eligibility criteria (not primary HNSCC), leaving 345 for analysis. Based on "self-report," 136 were classified as AA, 204 as CA, and 5 as "other" race. A summary of patient characteristics by race is shown in Table 1 . The characteristics of the 321 for whom stage at diagnosis is available are shown by stage (early or late) in Table 2 .
Ancestry Informative Markers
The distributions of West African and European genetic ancestry for self-reported CA, AA, and other are shown in Figures 1 and 2 , respectively. The range of West African genetic ancestry for our entire cohort was 0.004 to 0.992. Given misclassifications and the historical classification of AA in the United States, we included all African Americans with 15% or more West African ancestry in our statistical analyses. Four of 136 subjects who self-reported African American race had WA genetic ancestry under 15% (0.4%, 1.5%, 5.9%, and 6.8%), leaving 132 for subanalysis of genetic race.
Results for "Self-Reported" Subject Analyses
The associations with stage shown in Table 2 were assessed using logistic regression models. The odds ratios (ORs) and P values for these models are shown in Table 3 . There were significant univariate associations for site (P ≤ .001) and
(self-reported) race (P = .04). In the multivariate model, site as OP (OR = 2.72; 95% confidence interval [CI], 1.22-6.06; P = .014) and HP (OR = 3.36; 95% CI, 1.16-9.76; P = .026) remained an independent factor for late stage. However, the adjusted odds ratio for self-reported African American race (1.48; P = .163) in the multivariate analysis was reduced from 1.64 (P = .040) in the univariate analysis, without statistical significance.
Associations with time to death using Cox regression models are shown in Table 4 . There were significant univariate associations with stage (P = .002), age (P ≤ .001), and cancer site (P ≤ .001). Self-reported race was not associated with time to death (P = .386). In the multivariable model, the overall P value for site was not quite significant (P = .007), but 3 of the individual site-to-site comparisons vs larynx had hazard ratios (HRs) large enough to be clinically important (OP: HR = 2.24, P = .036; HP: HR = 1.92, P = .054; OC: HR = 1.81, P = .074). Late stage (HR = 1.63; 95% CI, 1.20-2.22; P = .002), age >65 (HR = 2.28; 95% CI, 1.51-3.46; P < .001), and site as OC and HP (OC: HR = 1.48, 95% CI, 1.00-2.19, P = .049; HP: HR = 2.35, 95% CI, 1.46-3.76, P < .001) were independent variables for poor prognosis. 
Results for AA Subgroup Analyses Using WA Genetic Ancestry
The subgroup logistic regression odds ratio estimates for late vs early stage are shown in Table 5 . Gender was a significant variable (univariate analysis), with male AA more likely to present with late stage than female AA (OR = 2.35; 95% CI, 1.04-5.30, P = .039) without statistical significance in the multivariate model (P = .070). Cancer site in the univariate analysis (P = .118) emerged as an independent variable in the multivariable model for site as other (OR = 0.12; 95% CI, 0.02-0.78; P = .026), indicating a reduced risk of late stage for site as other when compared with the larynx. Hazard ratios from Cox survival models are shown in Table  6 . Significant univariate risk factors, late stage (P = .02) and site (P = .002), remained in the multivariate model. Self-reported AAs with 15% or more West African ancestry with cancer site in the oropharynx was an independent predictor of poorer survival (OR = 2.24; 95% CI, 1.06-4.76; P = .036). Site as HP and OC had hazard ratios large enough to be clinically important (HP: HR = 1.92, P = .054; OC: HR = 1.81, P = .074). Late stage persisted as an independent variable for poor survival (OR = 1.84; 95% CI, 1.06-3.22; P = .032).
There is little evidence of an association between WA genetic ancestry and mortality in either univariate (HR = 0.92, P = .878) or multivariable (HR = 1.02, P = .974) analysis. However, the hazard ratio confidence intervals were wide, with large upper bounds (2.59 and 3.06, respectively), so an association with WA genetic ancestry cannot be definitively ruled out.
Discussion
We found no association between WA genetic ancestry and diagnosis (early vs late stage) and prognosis (overall survival) outcomes among HNSCC patients who identified themselves as African American. The rationale for the cutoff of >15% WA genetic ancestry includes the misclassification of study subjects 32 and the historical classification schema of the one-drop rule to denote AAs. The wide range of West African genetic ancestry for our cohort (39% self-reported AAs), illustrated in Figure 1 , is similar to previous findings by us and others. 27, 28, 33 Only 5% of self-reported AA had more than 95% WA ancestry, with 27% having less than 60% WA ancestry. The latter contrasted with more than 48% of whites with more than 95% European American ancestry. Our figures highlight that variation within so-called racial groups deconstructs traditional racial categorization. 34 The lack of association with HNSCC outcomes for AA based on genetic ancestry contrasted with that of race as self-classified AA. For our primary HNSCC cohort, self-reported AA ethnicity revealed a univariate risk factor for late stage (OR = 1.64, P = .040), but in the multivariable model, it had a reduced adjusted odds ratio (1.46; P = .163). Thus, our data may be consistent with a reduced but still clinically important association between AA ethnicity and stage. For overall survival, neither self-report nor genetic ancestry was associated with mortality.
For WA genetic ancestry and self-report as AA, cancer site remained a uniformly independent risk factor for both late stage and survival. HNSCC, often treated as a single entity, is in fact a heterogeneous group of tumors, and outcome of both diagnosis and prognosis is strongly influenced by the anatomic site of the primary tumor. 25, 35 In our study, among all HNSCC cohort patients, influence of location of the primary tumor on late-stage diagnosis, with larynx as the reference site, was the highest for cancer site as HP, followed by OP. Both OC and HP (and not OP) were predictors of poorer survival. When we stratified the AA group by WA genetic ancestry, site as other had a reduced risk of late stage when compared with the larynx. Interestingly, for survival, site as OP was independently associated with poorer survival (OP: HR = 2.24, P = .036) and may reflect a likely lower prevalence of HPV infection among AAs with oropharyngeal cancer. 16 The Settle et al 16 study found that poorer survival outcomes for AAs vs CAs with oropharyngeal tumors were attributable to racial differences in the prevalence of HPV-positive tumors; HPV prevalence in AAs was significantly lower than in CAs, with similar survival outcomes for HPV-negative AA and CA patients. Our data on site concur with previously reported HNSCC diagnosis and prognosis outcomes from our group. 25 There is abundant epidemiological evidence that selfidentified race/ethnicity is associated with differences in cancer incidence and mortality. Some examples include prostate cancer 36 and early-onset breast cancer. 37 In analyses by race and ethnicity, 38 AA men and women have 40% and 18% higher death rates from all cancers combined than CA men and women, respectively.
Increases in the incidence of cancer of the head and neck among minority groups 39 complement the 1998 "National Cancer Data Base Report on Cancer of the Head and Neck," 13 which showed a 10.0% proportionate increase in AA patients (from 8.0% to 8.8%) and a 21.4% proportionate increase in Hispanic patients (from 2.8% to 3.4%). The disproportionate increase in the number of head and neck mucosal cancers in AAs as compared with CAs is supported by other studies. In HNSCC, racial disparity also extended to disease stage, with a greater proportion of advanced-stage cancers (stages III and IV) occurring among lower income groups, the geographic region of the Southeast, and AAs. 13, 14 Variance in genetic background of study subjects is becoming more of an issue with the increasing number of genetic association studies on complex disease. Differences in genetic background among study individuals may affect the power and reliability of genetic association studies. 24, 32, 40 Methods to detect and control for differences in ancestry in genetic association studies use AIMs. AIMs have high utility in biomedical research because they can be used to accurately measure individual ancestry (IA) of subjects enrolled in studies. Most important, these IA estimates can be used to control for heterogeneity in genetic studies in recently admixed populations such as African Americans and Hispanic Americans.
We believe that this is the first report to look at diagnosis and prognosis outcomes in HNSCC based on genetic race. In this study, only self-reported race was associated with stage. Stratification within the AA group by West African genetic ancestry revealed no correlation with stage or survival, pointing to the causes of HNSCC disparities as likely caused by social rather than biological factors. These findings have clinical relevance for the evaluation of health disparities. Given the heterogeneity in the AA population, genetic ancestry rather than self-reported racial designation can reduce potential confounding effects due to population admixture and control for heterogeneity, bringing into sharper focus ethnic differences for cancer risk and prognosis in HNSCC.
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